Cascadian Therapeutics, Inc. (CASC) Downgraded to Strong Sell at ValuEngine
Cascadian Therapeutics, Inc. (NASDAQ:CASC) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Friday.
A number of other research analysts have also recently weighed in on the stock. Cowen and Company reissued a “buy” rating on shares of Cascadian Therapeutics in a research note on Tuesday, May 9th. Zacks Investment Research cut shares of Cascadian Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 19th. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $4.00 price objective on shares of Cascadian Therapeutics in a research note on Wednesday, May 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $6.17.
Shares of Cascadian Therapeutics (NASDAQ:CASC) traded down 0.28% on Friday, hitting $3.61. The stock had a trading volume of 334,501 shares. The stock’s market cap is $182.50 million. Cascadian Therapeutics has a one year low of $3.18 and a one year high of $10.98. The company’s 50 day moving average is $3.83 and its 200 day moving average is $3.96.
Cascadian Therapeutics (NASDAQ:CASC) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.06. During the same quarter in the previous year, the firm earned ($1.57) EPS. Equities research analysts predict that Cascadian Therapeutics will post $5.02 EPS for the current fiscal year.
A number of hedge funds have recently made changes to their positions in CASC. State of Wisconsin Investment Board purchased a new stake in shares of Cascadian Therapeutics during the second quarter worth about $104,000. BlueCrest Capital Management Ltd purchased a new stake in shares of Cascadian Therapeutics during the first quarter worth about $122,000. New York State Common Retirement Fund purchased a new stake in shares of Cascadian Therapeutics during the second quarter worth about $136,000. Citadel Advisors LLC purchased a new stake in shares of Cascadian Therapeutics during the first quarter worth about $142,000. Finally, Rhumbline Advisers purchased a new stake in shares of Cascadian Therapeutics during the second quarter worth about $143,000. Hedge funds and other institutional investors own 82.55% of the company’s stock.
Cascadian Therapeutics Company Profile
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Stock Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related stocks with our FREE daily email newsletter.